ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

2025-08-07 03:57:55 ET

ACADIA Pharmaceuticals Inc. (ACAD)

Q2 2025 Earnings Conference Call

August 06, 2025, 4:30 PM ET

Company Participants

Al Kildani - Corporate Participant

Catherine E. Owen Adams - CEO & Director

Elizabeth H. Z. Thompson - Executive VP and Head of Research & Development

Mark C. Schneyer - Executive VP & CFO

Thomas Andrew Garner - Executive VP & Chief Commercial Officer

Conference Call Participants

Leo Gene Watson - Mizuho Securities USA LLC, Research Division

Malcolm Hoffman - BMO Capital Markets Equity Research

Marc Harold Goodman - Leerink Partners LLC, Research Division

Michael H. Riad - Morgan Stanley, Research Division

Ritu Subhalaksmi Baral - TD Cowen, Research Division

Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division

Tazeen Ahmad - BofA Securities, Research Division

Tessa Thomas Romero - JPMorgan Chase & Co, Research Division

Yatin Suneja - Guggenheim Securities, LLC, Research Division

Ami Fadia - Needham & Company, LLC, Research Division

Ashwani Verma - UBS Investment Bank, Research Division

Brian Corey Abrahams - RBC Capital Markets, Research Division

David Timothy Hoang - Deutsche Bank AG, Research Division

Jason Nicholas Butler - Citizens JMP Securities, LLC, Research Division

Julian Hung - Stifel Nicolaus Canada Inc., Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Gerald, and I'll be your host for today. I would now like to turn the conference over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.

Al Kildani

Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's second quarter 2025 financial results. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us today is Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing thoughts before we open up the call for your questions. We are using supplemental slides, which are available on our website's Events & Presentations section....

Read the full article on Seeking Alpha

For further details see: